George Clinical Rebrands as Emerald Clinical Trials

Singapore - Emerald Clinical Trials, formerly known as George Clinical, has officially announced its rebranding, a move that reflects the company's growth and commitment to enhancing safety and transparency in global clinical research.

This strategic name change emphasizes the company's established reputation as a dependable and adaptable contract research organization (CRO). It aims to mitigate the global risks associated with clinical development by leveraging over 20 years of therapeutic and local expertise.

Emerald Clinical Trials will continue to offer comprehensive services across all therapeutic areas, with a focus on delivering impactful solutions while advancing innovations that contribute to the evolution of global clinical research practices. The organization boasts a strong track record in oncology and cardio-renal metabolic diseases (CRM) and possesses proven expertise in the Asia-Pacific region, establishing itself as a distinguished player on the international clinical research stage. With operations in 42 countries and partnerships extending to 70 countries, the company ensures seamless execution of clinical trials worldwide.

The new brand identity highlights the exceptional efforts of Emerald Clinical Trials and showcases the depth and breadth of its experience to a broader audience. It reflects a strong commitment to patients, clients, and partners.

Emerald Clinical Trials prioritizes customer-centric approaches that foster long-term relationships grounded in trust, reliability, and measurable outcomes. The organization's ability to provide predictability in clinical studies is underscored by a history of repeat business, industry accolades for excellence, and consistent performance in therapy market launches.

Over the past two decades, Emerald Clinical Trials has focused on delivering high-quality studies that blend global reach with a personalized touch. The organization combines the resources and expertise of a large CRO with the dedicated support and flexibility of a smaller partner, ensuring that each client, from emerging biotech firms to leading pharmaceutical companies, receives the tailored, practical assistance necessary to minimize risks in their clinical programs.

Dr. Daniel Tillett, CEO of Race Oncology, a client of Emerald, noted the importance of working with a CRO that adopts a flexible approach and provides solutions tailored to the specific needs of each study. He emphasized the importance of agility for biopharma companies seeking partners who evolve alongside them rather than hinder their progress with bureaucratic inefficiencies, a strength that Emerald Clinical Trials embodies.

Emerald Clinical Trials is a leading global clinical research organization servicing over 100 biotechnology firms and six of the top ten pharmaceutical companies. Headquartered in Singapore, the organization provides comprehensive clinical trial services worldwide and offers solutions for all phases of studies. For more information, visit www.emeraldclinical.com.